Skip to main content
. 2017 Feb 16;22(3):264–271. doi: 10.1634/theoncologist.2016-0223

Table 3. Summary of AEs in the safety and MET subgroup populations.

image

*Grade 5 AEs were cerebrovascular accident, respiratory failure, and sepsis.

Abbreviations: AE, adverse event; IHC, immunohistochemistry; MET, mesenchymal‐epithelial transition; Onartuzumab, onartuzumab plus bevacizumab plus mFOLFOX‐6; Placebo, placebo plus bevacizumab plus mFOLFOX‐6.